With oncolytic virus therapeutics continuing to demonstrate their clinical potential in immuno-oncology, they have become hot commodities with companies looking to gain a foothold in the space.
The Affordable Care Act hasn't been repealed and replaced for now. The biopharma sector was hoping that the introduction of a new bill would help resolve a number of thorny issues – including drug pricing – that have created headwinds for them for well over a year. For the time being, companies will have to assume it is business as usual until the subject of health care returns to the top of the administration's agenda once again.
Research on the potential of oncolytic viruses to treat various cancer types has waxed and waned over the past decade as promising early results failed to translate into clinical successes. However, these cancer destroying missiles are now firmly back on the industry's radar screen following the late 2015 FDA approval of the first oncolytic virus agent, Amgen Inc.'s Imlygic (talimogene laherparepvec) for nonresectable metastatic melanoma.
With oncolytic virus therapeutics continuing to demonstrate their clinical potential in immuno-oncology, they have become hot commodities with companies looking to gain a foothold in the space. As a result, biotechnology companies with promising technologies are attracting the attention of major biopharmaceutical companies. In part 2 of our feature on oncolytic viruses, we examine the deals landscape in this area, which in the past 12 months has generated a number of major transactions involving big pharma companies.
Research on the potential of oncolytic viruses to treat various cancer types has waxed and waned over the past decade as promising early results failed to translate into clinical successes. However, these cancer destroying missiles are now firmly back on the industry's radar screen following the late 2015 FDA approval of the first oncolytic virus agent, Amgen Inc.'s Imlygic (talimogene laherparepvec) for nonresectable metastatic melanoma. The therapeutic is derived from a herpes simplex virus that has been genetically engineered to infect cancer cells and to generate granulocyte macrophage colony-stimulating factor (GM-CSF).
Like their biopharmaceutical colleagues, publicly listed medical technology companies have roared out of the gate this year as investors flood back into health care. Companies have benefited from record-breaking market highs being driven by a increased optimism that the U.S. economy is poised to enjoy better times ahead. To track the market progress of the sector, we have created the Medical Devices Index, which will complement the MDD Stock Report. This price weighted index will record and track on a monthly basis the stock price performance of 20 of the leading medical technology companies...
Like their biopharmaceutical colleagues, publicly listed medical technology companies have roared out of the gate this year as investors flood back into health care. Companies have benefited from record-breaking market highs being driven by a increased optimism that the U.S. economy is poised to enjoy better times ahead.
Like their biopharmaceutical colleagues, publicly listed medical technology companies have roared out of the gate this year as investors flood back into health care. Companies have benefited from record-breaking market highs being driven by a increased optimism that the U.S. economy is poised to enjoy better times ahead.
It has been a remarkable start to the year. Two months in and who would have predicted that the Dow Jones Industrial Average would have soared past 21,000 and the Nasdaq Biotech Index return a year-to-date (YTD) gain of more than 12 percent? It has been an unexpected, but welcome, turn of events.
It used to be the case that achieving a successful IPO was cause to pop the champagne corks for the founders and employees of newly graduating public companies. However, there is mounting evidence, particularly among technology companies at least, that they are resisting the temptation to rush into the public limelight with an IPO and choosing to remain private much longer than was the case a decade or so ago.
